Sept 3 (Reuters) - AstraZeneca Plc said the U.S. Food and Drug Administration had approved a new dose of its blood thinner, Brilinta, for patients with a history of heart attack beyond the first year.
The health regulator approved Brilinta tablets at a new 60 mg dose, the company said on Thursday. (http://bit.ly/1N65F0b) (Reporting By Samantha Kareen Nair in Bengaluru; Editing by Maju Samuel)
Finance expert Suze Orman has voiced concerns about the impact of climate change on property insurance costs, asserting it could threaten the American dream of homeownership. Orman, 72, faced a $28,000 annual insurance quote for her Florida oceanside condo, leading her to forego coverage entirely. She highlights a troubling trend where soaring insurance costs driven by frequent and severe weather events may deter Americans from buying homes. Don't Miss: For many first-time buyers, a house is abo
Here's what could happen next to Meta Platforms' stock.
After Congress approved billions of extra funding for tax compliance, the Internal Revenue Service pledged it would get tougher on rich taxpayers and corporations while avoiding extra scrutiny of middle-class households.
After a dismal quarter for Tesla, CEO Elon Musk tried to reassure investors the company’s real value was its effort to perfect self-driving cars.
Six teams managing nearly $15 billion in total assets quit JPMorgan Chase’s brokerage unit to join competitors last Friday. Here’s what may have triggered their departures.
When it comes to reliable passive income, these three dividend-paying companies are best in breed.
Billionaire investors are ditching the "infrastructure backbone" of the artificial intelligence (AI) revolution in favor of two industry-leading, irreplaceable AI stocks.
The rally attempt is gaining steam. Tesla soared as Elon Musk said "affordable" EVs will come in 2025 and touted robotaxis.
The premier name among retail REITs, along with a 14%-yielding REIT that's returned $25 billion to its shareholders since going public, make for sensational buys right now.
If even Plug Power can't earn profits from fuel cell hydrogen, what hope is there for Bloom Energy and FuelCell Energy?